Title: Effects of glucagon‐like peptide‐1 receptor agonists on kidney function and safety in type 2 diabetes patients.
Authors: Kim, Min Kyung; Kim, Doo‐Man
Abstract: GLO:BDC3/01jun21:jdi13552-toc-0001.jpg PHOTO (COLOR): . gl Type 2 diabetes mellitus is the leading cause of chronic kidney disease (CKD) and almost 40% of type 2 diabetes patients develop diabetic kidney disease (DKD), which is characterized by reduced estimated glomerular filtration rate (eGFR) and/or increased albuminuria. Glucagon-like peptide-1 receptor agonists have been recommended in diabetic kidney disease patients. Recently, several clinical trials have reported that some newer glucose-lowering drugs, including sodium-glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide-1 receptor agonists (GLP-1RAs), have beneficial effects on the kidneys in type 2 diabetes patients.
Subjects: GLUCAGON-like peptide-1 receptor; TYPE 2 diabetes; GLUCAGON-like peptide-1 agonists; KIDNEY physiology; PEOPLE with diabetes
Publication: Journal of Diabetes Investigation, 2021, Vol 12, Issue 6, p914
ISSN: 2040-1116
Publication type: Academic Journal
DOI: 10.1111/jdi.13552

Effects of glucagon‐like peptide‐1 receptor agonists on kidney function and safety in type 2 diabetes patients.

Kim, Min Kyung; Kim, Doo‐Man